Document is current

Article History

Accepted: 23 June 2024

First Online: 17 July 2024

Declarations

:

: The study was approved by the Bioethics Committee at the Regional Medical Council in Poznan, Poland (approval no. 46/2019) and Poznan University of Medical Sciences (approval no. 672/18).

: Freely-given, informed consent to participate in the study was obtained from all participants (or their parent or legal guardian in the case of children under 16). The tissues were collected in MedPolonia Hospital (Poznan, Poland) and Poznan University of Medical Sciences. No tissues were obtained from prisoners.

: Not applicable.

: MS is CMO and shareholder of Dystrogen Therapeutics Technology Polska z o.o. the company that holds a license for DT-DEC01 therapy. MS is the inventor on the patent application filed by University of Illinois at Chicago related to chimeric cell therapy for Duchenne muscular dystrophy (WO/2016/201182). The author declares a potential conflict of interest. KS is CEO and shareholder of Dystrogen Therapeutics Corp. The author declares a potential conflict of interest. KB, AZ, KJ are Dystrogen Therapeutics Corp. employees.